hero image

Medical information and drug safety will forever be intertwined. When someone calls the toll-free number listed on a drug package to ask a question about a product, it’s not uncommon for an adverse event (AE) to be uncovered in the course of a conversation between the caller and the agent. This means that the agent identifies a potential side effect or product safety issue from the details shared by a caller, either directly or indirectly.

The Continuity Advantage

Once the capture of the AE has taken place, a strictly regulated domino effect of processing and reporting that AE needs to occur. Ensuring a seamless transition to the drug safety or pharmacovigilance team from medical information is a priority.

Teams working side-by-side in medical information and drug safety departments offer a true “continuity advantage” to the pharmaceutical company, consumer and healthcare provider.


Benefits include:


The end result means that a consumer can feel assured that any issues are handled in a swift manner by trained professionals, and the pharmaceutical company receives accurate and important information at their fingertips — not only for regulatory reporting, but to inform of needed immediate product changes or future improvements.


Related Articles